ImmuCell Reports Q2 2025 Financial Results: Product Sales Up 18%, Net Income $502,000

ImmuCell Corporation announced unaudited financial results for Q2 2025, with product sales increasing 18% to $6.4mln compared to Q2 2024. Sales for the six-month period ended June 30, 2025, rose 14% to $14.5mln, and for the twelve-month period, increased 22% to $28.3mln. The company improved its gross margin to 44% and 43% during the three-month and six-month periods, respectively, resulting in net income of approximately $502,000 and $1.9mln.